Trial reportFrontiers in neurology2026
Bioequivalence of tegomil fumarate gastro-resistant capsules versus dimethyl fumarate gastro-resistant capsules under different fed conditions: two randomized, crossover, phase I studies.
Trial report in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tegomil fumarate is a newly approved treatment for relapsing-remitting multiple sclerosis. Two phase I studies were performed under different fed conditions to evaluate the bioequivalence and tolerability of tegomil fumarate versus dimethyl fumarate in healthy volunteers. Methods: These were single-center, open-label, randomized, crossover (full replicate design), phase I studies. In both studies, healthy individuals aged 18-55 years received a single dose of tegomil fumarate (348.4 mg gastro-resistant hard capsule; "test") or an equimolar dose of dimethyl fumarate based on monomethyl fumarate (MMF) release (240.0 mg gastro-resistant hard capsule; "reference"). Participants were randomized to one of two treatment sequences (test-reference-test-reference or reference-test-reference-test), with 7 days between each drug administration. Before each drug administration, participants in Study 1 consumed a low-fat, low-calorie meal ("low-fed"), while those in Study 2 consumed a high-fat, high-calorie meal ("fed"). Pharmacokinetic parameters for MMF (active metabolite in both drugs) and adverse events (AEs) were assessed. Results: In total, 70 participants were enrolled (Study 1, Conclusion: These studies demonstrated the tolerability of tegomil fumarate in healthy volunteers. Pharmacokinetic analyses showed that a single dose of 348.4 mg tegomil fumarate released the same amount of MMF as an equimolar dose of 240 mg dimethyl fumarate under both low-fed (low-calorie, low-fat) and fed (high-calorie, high-fat) dietary conditions. Clinical trial registration: Agenţia Medicamentului şi Dispozitivelor Medicale [AMDM]; https://amdm.gov.md/ro, MMF-BEFI-07-TFB/24 (Rg04-000227) (Study 1; registered September 4, 2024); MMF-BEFI-06-TFB/22 (Rg04-000165) (Study 2; registered July 10, 2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.